Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Synthon Biopharmaceuticals Relaunches as Byondis
Details : Byondis is expecting results from its pivotal TULIP® Phase III trial comparing SYD985 to physician's choice treatment in patients with HER2-positive metastatic breast cancer.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 16, 2020
LOOKING FOR A SUPPLIER?